Overview

Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)

Status:
Completed
Trial end date:
1994-06-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Hydroxyurea